Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Equities researchers at B. Riley issued their Q3 2018 earnings estimates for Dicerna Pharmaceuticals in a research note issued to investors on Thursday, August 9th. B. Riley analyst M. Kumar anticipates that the biopharmaceutical company will earn ($0.13) per share for the quarter. B. Riley also issued estimates for Dicerna Pharmaceuticals’ Q4 2018 earnings at ($0.13) EPS, Q1 2019 earnings at ($0.34) EPS, Q2 2019 earnings at ($0.33) EPS, Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($0.32) EPS, FY2019 earnings at ($1.29) EPS, FY2020 earnings at ($0.54) EPS, FY2021 earnings at ($1.33) EPS and FY2022 earnings at ($0.10) EPS.

Several other equities research analysts have also issued reports on the stock. Chardan Capital reiterated a “hold” rating and set a $14.50 target price on shares of Dicerna Pharmaceuticals in a research report on Monday. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Stifel Nicolaus lifted their target price on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. ValuEngine lowered shares of Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 2nd. Finally, HC Wainwright reiterated a “hold” rating and set a $14.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $13.54.

Shares of Dicerna Pharmaceuticals stock opened at $14.76 on Monday. Dicerna Pharmaceuticals has a 1 year low of $2.69 and a 1 year high of $15.80. The company has a market cap of $773.07 million, a price-to-earnings ratio of -4.06 and a beta of 2.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 6.95.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.79 million.

Several hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth approximately $102,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth approximately $113,000. Caxton Corp purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth approximately $125,000. Jane Street Group LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth approximately $136,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Dicerna Pharmaceuticals during the second quarter worth approximately $178,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Article: Price to Earnings Ratio (PE)

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.